一线PARPi维持治疗后铂敏感复发卵巢癌二次肿瘤细胞减灭术的安全性与疗效
回顾性分析30例一线PARPi维持治疗后铂敏感复发卵巢癌患者接受二次肿瘤细胞减灭术(SCS)的资料。SCS后中位二次无进展生存(PFS2)为18.5个月,BRCA突变者25.7个月优于野生型14.1个月(P=0.028),3年总生存率90%,术后并发症4例(13%),30天内无死亡。
要点
- SCS后中位PFS2为18.5个月,BRCA突变者25.7个月 vs 野生型14.1个月(P=0.028)。
- 3年总生存率为90%,随访期内3例死亡。
- 术后并发症4例(13%,4/30),30天内无死亡。
核心结论
- 对于预期可达到R0切除的PARPi一线维持治疗后复发的铂敏感卵巢癌,SCS可作为安全且疗效可靠的二线治疗方案。
研究设计与样本
- 回顾性收集2018年1月至2024年6月接受SCS的30例PARPi一线维持治疗后铂敏感复发卵巢癌患者的临床病理资料及预后信息。
- 采用Kaplan-Meier法分析二次疾病无进展生存(PFS2)时间及3年总生存(OS)率。
主要发现
- 30例患者确诊时中位年龄51.3岁,初次肿瘤细胞减灭术40%(12/30)、新辅助化疗+间歇性肿瘤细胞减灭术60%(18/30),93%(28/30)达到满意减瘤。
- BRCA1/2检测率97%(29/30),BRCA突变11例(37%,11/30)、野生型18例(60%,18/30)。
- 中位PARPi维持治疗时间11.9个月,BRCA突变者19.2个月、野生型者10.1个月。
- SCS术后单病灶9例(30%,9/30)、寡病灶3例(10%,3/30)、多病灶18例(60%,18/30),满意减瘤97%(29/30)。
- 中位随访28.0个月,19例(63%,19/30)二次复发,SCS后中位PFS2为18.5个月,BRCA突变者25.7个月 vs 野生型14.1个月(P=0.028),3年OS率90%。
关键数值与推荐
- SCS后中位PFS2为18.5个月,BRCA突变患者25.7个月 vs BRCA野生型患者14.1个月(P=0.028)。
- 随访期内3例死亡,3年OS率为90%。
- 术后并发症4例(13%,4/30):1例术后第1天低血容量性休克转重症监护病房,1例术后第7天输尿管瘘行输尿管支架置入术,2例切口延迟愈合;SCS后30天内无死亡。
临床怎么用
- 作者认为,对于预期可达到R0切除的PARPi一线维持治疗后复发的铂敏感卵巢癌,SCS可作为安全且疗效可靠的二线治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effectiveness and safety of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent epithelial ovarian cancer who progressed after first-line maintenance therapy with poly adenosine diphosphate ribose polymerase inhibitor (PARPi). Methods: Clinical pathological data and prognostic information were retrospectively collected from 30 ovarian cancer patients who underwent SCS between January 2018 and June 2024. The Kaplan-Meier method was used to analyze the second progression-free survival (PFS2) time and 3-year overall survival (OS) rate. Results: (1) Primary treatment: the median age at diagnosis was 51.3 years. A total of 40% (12/30) patients underwent primary debulking surgery with an expectation of achieving no gross residual disease (R0), while 60% (18/30) received neoadjuvant chemotherapy and interval debulking surgery. Optimal cytoreduction was achieved in 93% (28/30) of patients. BRCA1/2 gene testing was performed in 29 patients (testing rate 97%, 29/30), identifying 11 BRCA-mutated (37%, 11/30) and 18 BRCA wild-type (60%, 18/30) patients. The median duration of PARPi maintenance therapy among the 30 patients was 11.9 months; patients with BRCA gene mutations had a median duration of 19.2 months, while those with BRCA wild-type had a median duration of 10.1 months. (2) Secondary surgery: pathologically confirmed recurrence patterns, single lesion in 9 patients (30%, 9/30), oligo-lesion (2 lesions) in 3 patients (10%, 3/30), and multi-lesion (≥3 lesions) in 18 patients (60%, 18/30). Among the 30 patients, optimal cytoreduction was achieved in 97% (29/30) of SCS patients, with suboptimal cytoreduction in 1 patient (3%, 1/30). Adjuvant chemotherapy included platinum+paclitaxel in 24 (80%, 24/30) patients and platinum+liposomal doxorubicin in 6 (20%, 6/30) patients. PARPi re-treatment was administered to 17 patients (57%, 17/30) after chemotherapy. (3) Efficacy and safety: as of the follow-up cutoff in June 2024, the median follow-up time was 28.0 months. A total of 19 (63%, 19/30) patients experienced the next recurrence. The median PFS2 time after SCS was 18.5 months. Recurrence occurred in 7 BRCA-mutated and 12 BRCA gene wild-type patients. Median PFS2 time was significantly longer in BRCA-mutated patients compared to BRCA wild-type patients (25.7 vs 14.1 months; P=0.028). Three deaths occurred during follow-up, resulting in a 3-year OS rate of 90%. Among the 30 patients, postoperative complications occurred in 4 patients (13%, 4/30). One patient developed a ureteral fistula on 7 days post-SCS requiring ureteral stenting, and one patient was transferred to the intensive care unit on 1 day post-SCS due to hypovolemic shock. No deaths occurred within 30 days after SCS. Conclusion: For platinum-sensitive recurrent ovarian cancer patients progressed after first-line PARPi maintenance therapy who are anticipated to achieve R0 resection, SCS represents a safe and effective second-line treatment option. 目的: 探讨接受聚二磷酸腺苷核糖聚合酶抑制剂(PARPi)一线维持治疗后铂敏感复发卵巢上皮性癌(卵巢癌)患者接受二次肿瘤细胞减灭术(SCS)的疗效及安全性。 方法: 回顾性收集2018年1月至2024年6月接受SCS的30例PARPi一线维持治疗后铂敏感复发卵巢癌患者的临床病理资料及预后信息。采用Kaplan-Meier法对患者的二次疾病无进展生存(PFS2)时间及3年总生存(OS)率进行分析。 结果: (1)初始治疗时:30例患者确诊卵巢癌的中位年龄为51.3岁;40%(12/30)的患者预期可达无肉眼可见残留灶(R0)切除而行初次肿瘤细胞减灭术,60%(18/30)的患者行新辅助化疗+间歇性肿瘤细胞减灭术;93%(28/30)的患者达到了满意减瘤[包括R0和残留灶<1 cm(R1)切除];29例患者行BRCA1/2基因检测,检测率97%(29/30),其中BRCA基因突变11例(37%,11/30)、BRCA基因野生型18例(60%,18/30)。30例患者的中位PARPi维持治疗时间为11.9个月,其中BRCA基因突变者为19.2个月、BRCA基因野生型者为10.1个月。(2)二次手术时:SCS术后病理检查显示,肿瘤单病灶、寡病灶(2个病灶)、多病灶(≥3个病灶)复发患者分别为9例(30%,9/30)、3例(10%,3/30)、18例(60%,18/30)。30例SCS术后患者中,29例(97%,29/30)达到满意减瘤,仅1例(3%,1/30)为不满意减瘤[残留灶≥1 cm(R2)切除];24例(80%,24/30)接受铂类药物+紫杉醇方案化疗,6例(20%,6/30)患者接受铂类药物+脂质体多柔比星方案化疗;化疗后17例(57%,17/30)接受了PARPi再治疗。(3)疗效及安全性:随访截止至2024年6月,中位随访时间为28.0个月。随访期内19例(63%,19/30)患者二次复发,SCS后中位PFS2时间为18.5个月,其中7例BRCA基因突变患者的中位PFS2时间显著优于12例BRCA基因野生型患者(25.7、14.1个月;P=0.028);随访期内3例患者死亡,3年OS率为90%。30例SCS患者中,4例(13%,4/30)出现SCS术后并发症,其中1例术后第1天因低血容量性休克转重症监护病房治疗,1例术后第7天出现输尿管瘘行输尿管支架置入术,2例切口延迟愈合。SCS手术后30 d内无死亡患者。 结论: 对于预期可达到R0切除的PARPi一线维持治疗后复发的铂敏感卵巢癌,SCS可作为安全且疗效可靠的二线治疗方案。.
引用
- Zhao YX, Yao HW, Zeng J, et al. [Safety and efficacy of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer after first-line PARPi maintenance therapy]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40854745. doi:10.3760/cma.j.cn112141-20241106-00591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。